GM-CSF deficiency or inhibition has been demonstrated to alleviate CRS and ICANS, increasing the anti-tumor effects of CAR-T cell therapies by deterring the local invasion of myeloid cells and T cells [90,91]. Here, CSF2 is linked to congenital rubella syndrome.